Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Bioprinting Scaffolding Technology Offers Potential for Regenerating Tissue

By BiotechDaily International staff writers
Posted on 27 Nov 2012
The groundbreaking technology of bioprinting is showing promise in building scaffolds in which to grow cells for regenerative medicine applications.

The study’s findings were published in the November 2012 issue of the journal Science. In the article, Prof. Brian, from the University of Manchester’s (UK) School of Materials assessed the hypothesis of employing printer technology to construct structures in which to grow cells, to help to regenerate tissue.

Both laser printer and inkjet technology can be used to build the three-dimensional (3D) scaffolds that cells can be grown in and also position the cells in these structures simultaneously. Prof. Derby clarified how bioprinting works, “Inkjet technology places the structure’s material in small droplets, which then solidify. More droplets are then placed on top of the previous ones in a specific pattern. The structure is built using this method that is generally referred to as additive manufacture. Laser printing uses light to solidify the structure’s substance layer upon layer. These methods have allowed us to develop very complex scaffolds which better mimic the conditions inside the body.”

The scaffold provides a surface for the cells to adhere, multiply, and flourish. Both the scaffold substance, composition, and its internal structure regulate the behavior and health of the cells inside. In his review article, Prof. Derby examined research where porous structures have been constructed through bioprinting. They are then positioned in the body to help act as a scaffold to encourage cell growth. The cells colonize the structure and it either dissolves or becomes part of the body. This type of treatment can help patients suffering from ailments such as cavity wounds. Clinical trials are ongoing worldwide to refine this technology, and according to Prof. Derby, it is moving towards becoming an established form of science.

Prof. Derby also studied how stem cells are being grown in printed structures that have been permeated with specific chemicals. The chemicals are inserted during the printing process and can determine the type of cell into which the stem cells develop. Stem cells, for instance, could be programmed to become cells that comprise cartilage or bone tissue.

However, there are drawbacks to the technology that is holding back advances such as the capability to grow a complete organ. Study findings have revealed that it is very challenging to actually print the cells at the same time as making the structure that will hold them. The stress on the cell as it goes through both the inkjet and laser process can injure the cell membrane. Cell survival rates have also been variable, ranging from between 40%-95%.

The technology is also a ways from being a research platform to clinical practice. Whereas scaffolds are being clinically trialed, essentially transplanting cells grown in an external structure into a patient is a more sophisticated process. It is still not possible at present to assure a consistent quality, which is required by medical device regulations.

However, studies are being conducted to grow external cells into tissue, such as a skin patch, and transplant that into a patient. Prof. Derby is currently working with ear, nose, and throat surgeons at the Manchester Royal Infirmary. He wants to use bioprinting to print cells without using a scaffold. The printed cells form a sheet that can be used for grafts inside the body, for example, in the nose or mouth.

Prof. Derby said, “It is very difficult to transplant even a small patch of tissue to repair the inside of the nose or mouth. Current practice, to transplant the patient’s skin to these areas, is regarded as unsatisfactory because the transplants do not possess mucous generating cells or salivary glands. We are working on techniques to print sheets of cells that are suitable for implantation in the mouth and nose.”

An area that Prof. Derby foresees is the ability to grow structures that can mimic cancerous tumors. These could then be used to evaluate new drugs, which it is hoped will further the search for more effective treatments. Prof. Derby concluded that there is a strong future for bioprinting and while growing organs is still quite a ways off, these recent developments are very encouraging.

Related Links:
University of Manchester



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.